PirlWF. Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr2004;32:32–9.
2.
NewportDJNemeroffCB. Assessment and treatment of depression in the cancer patient. J Psychosom Res1998;45:215–37.
3.
DavisMPKhawamEPozueloLLagmanR. Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project. Expert Rev Anticancer Ther2002;2:365–76.
4.
De BoerT. The pharmacologic profile of mirtazapine. J Clin Psychiatry1996;57:19–25.
5.
VariaIVenkataramanSHellegersCGersingKDoraiswamyPM. Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study. Psychopharmacol Bull2007;40:47–56.
6.
PasquiniMBiondiMCostantiniA. Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. Depress Anxiety2006;23:441–8.
7.
RajiMA. Management of chemotherapy-induced side-effects (letter). Lancet Oncol2005;6:357.
8.
TheobaldDEKirshKLHoltsclawEDonaghyKPassikSD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage2002;23:442–7.
9.
ThompsonD. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics2000;41:356–9.
10.
MinamiMEndoTHirafujiM. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther2003;99:149–65.
11.
PaeCU. Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. Prog Neuropsychopharmacol Biol Psychiatry2006;30:1143–5.
